Skip to main content
Top
Published in: CEN Case Reports 1/2022

01-02-2022 | Multiple Myeloma | Case Report

Critical peritonitis secondary to gastrointestinal mucormycosis in a peritoneal dialysis patient: a case report

Authors: Soken Hattori, Takashi Matono, Makoto Hirakawa, Yusuke Nakamata, Kazuhiro Okamura, Tomoya Hamashoji, Takuro Kometani, Takafumi Nakashima, Sho Sasaki, Ryosuke Minagawa, Kiyoshi Kajiyama

Published in: CEN Case Reports | Issue 1/2022

Login to get access

Abstract

Immunodeficient patients are susceptible to systemic fungal infections; however, these rarely cause secondary peritonitis. A 66-year-old man with multiple myeloma and diabetes mellitus on continuous ambulatory peritoneal dialysis (CAPD) presented with cloudy ascitic fluid. He had been treated with corticosteroids for 1 month for Tolosa–Hunt syndrome. We diagnosed peritoneal dialysis-related peritonitis caused by Enterococcus avium, removed the CAPD catheter, and initiated intravenous ampicillin. Computed tomography (CT) revealed an intramural gastric mass and a thinning ascending colon wall. Four days later, follow-up contrast-enhanced CT showed penetration of the ascending colon and rupture of the ileocolic artery. Emergency open surgery revealed hemorrhagic infarction with mucormycosis. We initiated intravenous liposomal amphotericin B 20 days after admission; however, he died 55 days later. Anatomical abnormalities, such as gastrointestinal perforation, should be considered for peritonitis in immunodeficient patients. Gastrointestinal mucormycosis is rare but fatal, resulting from a delay in diagnosis and consequent gastrointestinal perforation. For an early diagnosis and a favorable clinical outcome, it is important to consider the risk factors for mucormycosis, including corticosteroid use, diabetes, end-stage kidney diseases.
Literature
1.
go back to reference Li PK, Chow KM. Infectious complications in dialysis—epidemiology and outcomes. Nat Rev Nephrol. 2011;8(2):77–88.CrossRef Li PK, Chow KM. Infectious complications in dialysis—epidemiology and outcomes. Nat Rev Nephrol. 2011;8(2):77–88.CrossRef
2.
go back to reference Bloembergen WE, Port FK, Mauger EA, Wolfe RA. A comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol. 1995;6(2):184–91.CrossRef Bloembergen WE, Port FK, Mauger EA, Wolfe RA. A comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol. 1995;6(2):184–91.CrossRef
3.
go back to reference Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–53.CrossRef Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–53.CrossRef
4.
go back to reference Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi (Basel). 2019;5(1):26.CrossRef Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi (Basel). 2019;5(1):26.CrossRef
5.
go back to reference Sun HY, Singh N. Mucormycosis: its contemporary face and management strategies. Lancet Infect Dis. 2011;11(4):301–11.CrossRef Sun HY, Singh N. Mucormycosis: its contemporary face and management strategies. Lancet Infect Dis. 2011;11(4):301–11.CrossRef
6.
go back to reference Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S23-34.CrossRef Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S23-34.CrossRef
7.
go back to reference Katragkou A, Walsh TJ, Roilides E. Why is mucormycosis more difficult to cure than more common mycoses? Clin Microbiol Infect. 2014;20(Suppl 6):74–81.CrossRef Katragkou A, Walsh TJ, Roilides E. Why is mucormycosis more difficult to cure than more common mycoses? Clin Microbiol Infect. 2014;20(Suppl 6):74–81.CrossRef
8.
go back to reference Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018;56(suppl_1):93–101.CrossRef Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018;56(suppl_1):93–101.CrossRef
9.
go back to reference Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000;30(6):851–6.CrossRef Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000;30(6):851–6.CrossRef
10.
go back to reference Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int. 2016;36(5):481–508.CrossRef Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int. 2016;36(5):481–508.CrossRef
11.
go back to reference Dioverti MV, Cawcutt KA, Abidi M, Sohail MR, Walker RC, Osmon DR. Gastrointestinal mucormycosis in immunocompromised hosts. Mycoses. 2015;58(12):714–8.CrossRef Dioverti MV, Cawcutt KA, Abidi M, Sohail MR, Walker RC, Osmon DR. Gastrointestinal mucormycosis in immunocompromised hosts. Mycoses. 2015;58(12):714–8.CrossRef
12.
go back to reference Agha FP, Lee HH, Boland CR, Bradley SF. Mucormycoma of the colon: early diagnosis and successful management. AJR Am J Roentgenol. 1985;145(4):739–41.CrossRef Agha FP, Lee HH, Boland CR, Bradley SF. Mucormycoma of the colon: early diagnosis and successful management. AJR Am J Roentgenol. 1985;145(4):739–41.CrossRef
13.
go back to reference Skiada A, Lanternier F, Groll AH, et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European conference on infections in leukemia (ECIL 3). Haematologica. 2013;98(4):492–504.CrossRef Skiada A, Lanternier F, Groll AH, et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European conference on infections in leukemia (ECIL 3). Haematologica. 2013;98(4):492–504.CrossRef
14.
go back to reference Angebault C, Lanternier F, Dalle F, et al. Prospective evaluation of serum β-glucan testing in patients with probable or proven fungal diseases. Open Forum Infect Dis. 2016;3(3): ofw128.CrossRef Angebault C, Lanternier F, Dalle F, et al. Prospective evaluation of serum β-glucan testing in patients with probable or proven fungal diseases. Open Forum Infect Dis. 2016;3(3): ofw128.CrossRef
15.
go back to reference Issa NC, Koo S, Lynch RC, et al. Serum galactomannan and (1->3)-beta-d-glucan assays for patients with multiple myeloma and Waldenstrom’s macroglobulinemia. J Clin Microbiol. 2012;50(3):1054–6.CrossRef Issa NC, Koo S, Lynch RC, et al. Serum galactomannan and (1->3)-beta-d-glucan assays for patients with multiple myeloma and Waldenstrom’s macroglobulinemia. J Clin Microbiol. 2012;50(3):1054–6.CrossRef
16.
go back to reference Prattes J, Schneditz D, Pruller F, et al. 1,3-ss-d-Glucan testing is highly specific in patients undergoing dialysis treatment. J Infect. 2017;74(1):72–80.CrossRef Prattes J, Schneditz D, Pruller F, et al. 1,3-ss-d-Glucan testing is highly specific in patients undergoing dialysis treatment. J Infect. 2017;74(1):72–80.CrossRef
17.
go back to reference Marty FM, Koo S. Role of (1–>3)-beta-d-glucan in the diagnosis of invasive aspergillosis. Med Mycol. 2009;47(Suppl 1):S233-40.CrossRef Marty FM, Koo S. Role of (1–>3)-beta-d-glucan in the diagnosis of invasive aspergillosis. Med Mycol. 2009;47(Suppl 1):S233-40.CrossRef
18.
go back to reference Giacobbe DR, Del Bono V, Viscoli C, et al. Use of 1,3-β-d-glucan in invasive fungal diseases in hematology patients. Expert Rev Anti Infect Ther. 2017;15(12):1101–12.CrossRef Giacobbe DR, Del Bono V, Viscoli C, et al. Use of 1,3-β-d-glucan in invasive fungal diseases in hematology patients. Expert Rev Anti Infect Ther. 2017;15(12):1101–12.CrossRef
19.
go back to reference Lu J, Lee JH, Huang SY, et al. Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. Br J Haematol. 2017;176(5):743–9.CrossRef Lu J, Lee JH, Huang SY, et al. Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. Br J Haematol. 2017;176(5):743–9.CrossRef
20.
go back to reference Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556–69.CrossRef Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556–69.CrossRef
21.
go back to reference Ganz T, Nemeth E. Iron homeostasis in host defence and inflammation. Nat Rev Immunol. 2015;15(8):500–10.CrossRef Ganz T, Nemeth E. Iron homeostasis in host defence and inflammation. Nat Rev Immunol. 2015;15(8):500–10.CrossRef
22.
go back to reference Boshuizen M, Binnekade JM, Nota B, et al. Iron metabolism in critically ill patients developing anemia of inflammation: a case control study. Ann Intensive Care. 2018;8(1):56.CrossRef Boshuizen M, Binnekade JM, Nota B, et al. Iron metabolism in critically ill patients developing anemia of inflammation: a case control study. Ann Intensive Care. 2018;8(1):56.CrossRef
23.
go back to reference Morace G, Borghi E. Invasive mold infections: virulence and pathogenesis of mucorales. Int J Microbiol. 2012;2012: 349278.CrossRef Morace G, Borghi E. Invasive mold infections: virulence and pathogenesis of mucorales. Int J Microbiol. 2012;2012: 349278.CrossRef
24.
go back to reference Wandersman C, Delepelaire P. Bacterial iron sources: from siderophores to hemophores. Annu Rev Microbiol. 2004;58:611–47.CrossRef Wandersman C, Delepelaire P. Bacterial iron sources: from siderophores to hemophores. Annu Rev Microbiol. 2004;58:611–47.CrossRef
25.
go back to reference Khan FA, Fisher MA, Khakoo RA. Association of hemochromatosis with infectious diseases: expanding spectrum. Int J Infect Dis. 2007;11(6):482–7.CrossRef Khan FA, Fisher MA, Khakoo RA. Association of hemochromatosis with infectious diseases: expanding spectrum. Int J Infect Dis. 2007;11(6):482–7.CrossRef
Metadata
Title
Critical peritonitis secondary to gastrointestinal mucormycosis in a peritoneal dialysis patient: a case report
Authors
Soken Hattori
Takashi Matono
Makoto Hirakawa
Yusuke Nakamata
Kazuhiro Okamura
Tomoya Hamashoji
Takuro Kometani
Takafumi Nakashima
Sho Sasaki
Ryosuke Minagawa
Kiyoshi Kajiyama
Publication date
01-02-2022
Publisher
Springer Singapore
Published in
CEN Case Reports / Issue 1/2022
Electronic ISSN: 2192-4449
DOI
https://doi.org/10.1007/s13730-021-00628-4

Other articles of this Issue 1/2022

CEN Case Reports 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine